ScienceDaily PharmaceuticalsOriginal article
Bowel cancer “melted away” after immunotherapy, then stayed away
Phase 2positivepembrolizumabPositive
AI Analysis
Summary
NEOPRISM-CRC trial demonstrates that neoadjuvant pembrolizumab for stage two or three bowel cancer with specific genetic mutations showed zero cancer recurrence over nearly three years of follow-up in 32 patients. This short-course immunotherapy approach before surgery may offer a durable alternative to standard post-surgery chemotherapy.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Patients
32
Outcome Details
Zero cancer recurrence in 32 patients after nearly three years of follow-up with neoadjuvant pembrolizumab before surgery
Importance:6/10
Sentiment:
0.85
immunotherapycolorectal cancerneoadjuvant treatmentpembrolizumabNEOPRISM-CRC trialdurable response
Related Companies
Read the original article
Published by ScienceDaily Pharmaceuticals on October 10, 2026 6:42 PM